Trial Simulation, Drug Selection To Be Focus Of US FDA's Drug Development Modeling Pilot
Executive Summary
Meeting requests from sponsors that focus on safety prediction will also be prioritized.
You may also be interested in...
Complex Innovative Designs Pilot Likely Satisfies Industry's Disclosure Worries
US FDA says sponsors generally won’t need to publicly disclose company or product if selected for pilot, but rather elements about design of their complex trial.
US FDA's Complex Trial Design Pilot Might Be Handicapped By Disclosure Requirements
FDA wants to publicize some aspects of designs accepted into pilot, which might discourage industry participation.
US FDA Offers Sponsors More Attention For Sharing Complex Innovative Trial Designs
Pilot program will select two trial designs per quarter, but sponsors want to know how much information they must disclose.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: